ESMO 2023 – low-dose volrustomig hints at a therapeutic window
But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.
Bristol seeks novelty in TIGIT
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
Tivdak success could make life even harder for Iovance
Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.
Despite the setbacks, interest in TGF-β remains
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.